Precision oncology,
made smart.
Most patients with advanced cancer never get the genomic test that would tell their oncologist which therapy to start. OncoX builds diagnostics that change that — fast, ultra-sensitive, and designed to run in the labs that already serve them.
Half of advanced-cancer patients are denied the genomic testing that could guide their treatment.
Tissue is often insufficient, turnaround is too slow, and the equipment cost shuts most labs out. The result: patients start chemotherapy when they could have started a targeted therapy.
Source: DaCosta et al. JAMA Network Open 2025;8(7):e2519963.
All 11 recommended genes — in 1 test.
The 11 genes and 114 variants that determine which therapy a lung-cancer patient should start — covered in a single assay. LiquiSmart Lung detects 99% of the DNA mutations and >97% of the gene fusions known to drive non-small cell lung cancer (Cosmic v100), from a single FFPE block or a tube of blood.
The new benchmark in lung-cancer genomic testing — industry-leading sensitivity, 100% specificity.
Median panel-wide LoD95 on the standard input workflow. Performance holds at low input, where most NGS workflows fail.
LiquiSmart Lung
A fast, ultra-sensitive biomarker test for non-small cell lung cancer. Detects 99% of guideline-recommended DNA mutations and >97% of gene fusions — from a single FFPE block or a tube of blood, on standard real-time PCR hardware.
- Platform
- qPCR-based assay
- Indication
- Stage IB–IV NSCLC
- Sample
- FFPE tissue or 10 mL blood (PAXgene®)
- Turnaround
- Next-day results
- Coverage
- 11 genes · 114 variants · DNA + RNA
- Status
- CLIA / CAP validated · ISO 13485
A workflow your lab can adopt next week.
-
01
Target amplification
Selective enrichment of all guideline regions from DNA and RNA in parallel.
30 min hands-on · 1 h 25 m incubation -
02
Enzymatic cleanup
Removes off-target product so signal-to-noise stays clinical-grade.
10 min hands-on · 15 min incubation -
03
LiquiSmart reaction
Variant-discriminating chemistry that lights up only the alleles you're looking for.
35 min hands-on · 35 min incubation -
04
Detection
Real-time PCR readout on standard QuantStudio™ hardware your lab already runs.
15 min hands-on · 3 h 30 m run -
05
Report
Desktop analysis returns a clinician-ready report — actionable variants and confidence calls.
5 min hands-on · next-day result
Tested in the labs that set the standard.
- ISO 13485 manufacturing for reagents.
- CLIA-certified, CAP-accredited US laboratory clinical validation.
- CellCarta CRO independent validation for clinical-trial use in the US, EU and China.
- Consistent performance across multiple independent academic sites.
- Peer-reviewed publications in Frontiers in Oncology, Journal of Liquid Biopsy, and Translational Lung Cancer Research.
- Patient
- L.G.* · 71 years
- Diagnosis
- Stage IV NSCLC
- Sample
- Pleural biopsy — 10–15% tumor content
- Prior testing
- NGS & sequential PCR returned QNS
*Anonymized clinical case study, identifying details altered.
LiquiSmart Lung returned an actionable EGFR L858R mutation from the same low-content sample — enabling targeted therapy to begin immediately.
When the sample is small, the result still has to count.
L.G. presented with a large pleural effusion and pleural nodularity. Pleural fluid was aspirated, but the cell block had insufficient cellularity for molecular studies. A pleural biopsy confirmed NSCLC — but at 10–15% tumor content it was deemed quantity not sufficient for NGS or sequential PCR testing.
With no molecular result, L.G. was started on chemotherapy empirically. He did not tolerate it well.
One company. Every cancer that deserves better diagnostics.
LiquiSmart Lung is launched. Bladder, Prostate, Breast and Head & Neck are next — built on targeted NGS where deep multi-gene profiling matters most.
| Program | Indication | Platform | Discovery | Analytical | Clinical | Launch |
|---|---|---|---|---|---|---|
| LiquiSmart Lung | NSCLC, Stage IB–IV | qPCR (DNA + RNA) | ||||
| LiquiSmart Bladder | Urothelial carcinoma | Targeted NGS | ||||
| LiquiSmart Prostate | mCRPC | AR-aware NGS | ||||
| LiquiSmart Breast | HR+/HER2− mBC | Hotspot NGS + dPCR | ||||
| LiquiSmart H&N | HPV+/− HNSCC | Dual-track NGS |
Available in
India
Bringing precision oncology to where it's needed most.
- Ultra-sensitive biomarker testing in NSCLC
- Rapid results from FFPE tissue or blood
- Simultaneous DNA & RNA analysis
- Industry-leading sensitivity, 100% specificity
- Very low test failure rate
- No new instrument capex for the lab
The power
of smart.
Precision oncology should not be a privilege of geography. OncoX builds the diagnostics that make sure it isn't.
Talk to usBring molecular precision to your patients.
Request kits, access clinical data, or partner with us on a new indication. We respond within one business day.
Or write to us directly at aditi.datta@biositeindia.com
LiquiSmart Lung is for in vitro diagnostic use in jurisdictions where licensed; clinical performance study underway for CDSCO IVD approval in India. Other indications in development and not yet available for clinical use.